Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 6NETWORK 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Lymphoma 8Lung Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Hodgkin Disease 6Recurrence 3Kidney Neoplasms 2Urinary Bladder Neoplasms 1Testicular Neoplasms 1Teratoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1HIV Infections 1Carcinoma, Renal Cell 1Acquired Immunodeficiency Syndrome 1AIDS-Related Complex 1

Interventions

aldesleukin 65Cyclophosphamide 45fludarabine phosphate 30fludarabine 27Interleukin-2 24incomplete Freund's adjuvant 22Ipilimumab 17Specimen Handling 14MART-1 Antigen 14CTLA-4 Antigen 14sargramostim 13Magnetic Resonance Spectroscopy 13Biopsy 13montanide ISA 51 11Nivolumab 11Filgrastim 11Sorafenib 10Interferon-alpha 9trametinib 8pembrolizumab 8dabrafenib 8Sirolimus 7Bevacizumab 7temsirolimus 6Temozolomide 6Taxes 5Paclitaxel 5Introns 5Gene Expression Profiling 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Melanoma × Vinblastine × Clear all
NCT01196416 2019-11-18

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 1/2 Completed
14 enrolled 16 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡